Treatment of Prostate Cancer with a DBP-MAF-Vitamin D Complex to Target Angiogenesis and Tumorigenesis

Abstract

The purpose of this study has been to determine the efficacy of combined therapy using vitamin D binding protein-macrophage activating factor (DBP-maf) and vitamin D as therapy for human prostate cancer. We had found that in endothelial tube formation vitamin D and DBP-maf inhibited the tube formation. Both molecules were effective on their own however the vitamin D showed evidence of toxicity at higher concentration. We here show that the combination of vitamin D, at a level ineffective by itself(10 pM), and DBP-maf at concentrations as low as 100 ng/ml show potent synergistic behavior. We observed that DBP-maf inhibits the expression of urokinase-type plasminogen activator receptor (UPAR), a molecule whose expression has been linked with increased metastasis. We also observed reduced expression of p21 and p27 by DBP-maf but not by the control DBP. The expression of UPAR by DBP-maf may explain its potent activity on tumors.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Feb 01, 2008
Accession Number
ADA486241

Entities

People

  • Michael W. Fannon

Organizations

  • University of Kentucky

Tags

DTIC Thesaurus Topics

  • Angiogenesis
  • Biomedical Research
  • Blood
  • Cancer
  • Carrier Proteins
  • Cell Line
  • Cell Movement
  • Cells
  • Cytoskeleton
  • Endothelial Cells
  • Metastasis
  • Molecules
  • Neoplasms
  • Prostate Cancer
  • Proteins
  • Tumor Cell Line
  • Vitamin D

Readers

  • Marine Propulsion Engineering and Naval Architecture
  • Molecular and Cellular Biochemistry
  • Oncology (Cancer Research).